title: Progression of liver fibrosis in HCV-positive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen.
authors.affiliation: Hôpital Paul Brousse, Université Paris-Sud, Villejuif, France. faouzi.saliba@pbr.aphp.fr.
authors.forename: Faouzi
authors.initials: F
authors.lastname: Saliba
authors.forename: Frederik
authors.initials: F
authors.lastname: Nevens
mesh_terms: D000970:Antineoplastic Agents; D065095:Calcineurin Inhibitors / Q000008:administration & dosage*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D000068338:Everolimus / Q000008:administration & dosage*; D016174:Hepacivirus / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000175:diagnosis / Q000821:virology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008103:Liver Cirrhosis / Q000209:etiology / Q000473:pathology*; D016031:Liver Transplantation; D016032:Randomized Controlled Trials as Topic; D066027:Transplant Recipients
chemical_list: D000970:Antineoplastic Agents; D065095:Calcineurin Inhibitors; D018937:Hepatitis C Antibodies; D007166:Immunosuppressive Agents; D000068338:Everolimus